Tinklenberg Rebecca L, Murphy Shane D, Mochel Jonathan P, Seo Yeon-Jung, Mahaffey Alyssa L, Yan Yuqi, Ward Jessica L
Am J Vet Res. 2020 Apr;81(4):317-325. doi: 10.2460/ajvr.81.4.317.
To determine whether a dose-response relationship exists between short-term oral prednisone administration and common clinicopathologic variables, cardiovascular biomarkers, and systolic arterial blood pressure (SAP) in healthy dogs.
8 healthy Beagles.
Dogs underwent five 5-day experiments (no prednisone treatment [control condition] and prednisone administration at 0.5, 1, 2, and 4 mg/kg, PO, q 24 h), with a 9-day washout period between protocols. Analyses performed before and after treatments included a CBC, serum biochemical analysis, and determination of SAP, fractional excretion of electrolytes, urine protein-to-creatinine ratio, glomerular filtration rate (GFR), serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and plasma cortisol concentrations, and plasma renin activity. Linear mixed-effects modeling was used to compare changes in variables from baseline (day 1 for the same experiment) among treatment conditions.
Changes in serum glucose concentration and GFR were significantly greater after administration of prednisone at 4 mg/kg than for the control condition. Fractional excretion of sodium was decreased from baseline when dogs received 0.5, 1, or 4 mg of prednisone/kg, compared with results for the control condition. Several expected changes in clinicopathologic values were observed after prednisone administration at any dose. Changes in serum NT-proBNP concentration, plasma renin activity, and SAP did not differ from changes for the control condition at any prednisone dose.
Oral prednisone administration did not affect SAP, NT-proBNP concentration, or measures of renin-angiotensin-aldosterone system activation in healthy laboratory-housed dogs but was associated with relative increases in GFR and serum glucose concentration.
确定健康犬短期口服泼尼松给药与常见临床病理变量、心血管生物标志物及收缩期动脉血压(SAP)之间是否存在剂量反应关系。
8只健康比格犬。
犬只接受了5次为期5天的实验(无泼尼松治疗[对照条件]以及分别按0.5、1、2和4mg/kg口服泼尼松,每24小时一次),各实验方案之间有9天的洗脱期。治疗前后进行的分析包括全血细胞计数、血清生化分析以及SAP测定、电解质排泄分数、尿蛋白与肌酐比值、肾小球滤过率(GFR)、血清N末端B型脑钠肽前体(NT-proBNP)和血浆皮质醇浓度以及血浆肾素活性测定。采用线性混合效应模型比较各治疗条件下变量相对于基线(同一实验的第1天)的变化。
给予4mg/kg泼尼松后,血清葡萄糖浓度和GFR的变化显著大于对照条件。与对照条件相比,犬只接受0.5、1或4mg/kg泼尼松时,钠排泄分数较基线降低。给予任何剂量泼尼松后,观察到临床病理值有一些预期变化。在任何泼尼松剂量下,血清NT-proBNP浓度、血浆肾素活性和SAP的变化与对照条件的变化无差异。
口服泼尼松对健康实验犬的SAP、NT-proBNP浓度或肾素-血管紧张素-醛固酮系统激活指标无影响,但与GFR和血清葡萄糖浓度相对升高有关。